Pharmaceutical Ceftaroline fosamil powder 866021-48-9
10 -99 Pieces
≥ 100 Pieces
If you have your own design, please contact us, there will have a professional customer service to communicate with you.
Don't have your files right now?No worries, Check out our art tips for more information.
If over 500pcs, mass production will start until pre-production sample has been approved.
Est. 7 days production
|Product name||ceftaroline fosamil|
|Place of Origin||CN;SHA|
|Model Number||KL-ceftaroline fosamil|
|Shelf Life||2 Years|
|Type||Auxiliaries and Other Medicinal Chemicals|
|Grade Standard||Medicine Grade|
Packaging & Delivery
- Selling Units:
- Lead Time:
Quantity(Gram) 1 - 2000 2001 - 5000 >5000 Est. Time(days) 5 6 To be negotiated
Pharmaceutical Ceftaroline fosamil powder 866021-48-9Ceftaroline fosamil, brand name Teflaro in the US and Zinforo in Europe, is a fifth-generation cephalosporin antibiotic. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive bacteria. It retains the activity of later-generation cephalosporins having broad-spectrum activity against Gram-negative bacteria. It is currently being investigated for community-acquired pneumonia and complicated skin and skin structure infection.
|Item Name||ceftaroline fosamil|
|Package||Aluminum Bag;Drums;Paper Box Outside|
|Payment||Western Union;T/T;Trade Assurance;L/C|
Ceftaroline is a novel cephalosporin with activity against MRSA with phase III clinical trials for complicated skin and skin structure infections with reported non-inferior efficacy against MRSA compared to vancomycin and aztreonam. In 2009, ceftaroline had completed phase-III clinical trials for community-acquired pneumonia comparing it against ceftriaxone with non-inferior results and similar adverse reaction profile. However, only results for phase-II clinical trials in treatment of complicated skin and skin structure infections have been published. Sept 2009 : Phase III trials results reported. On September 8, 2010, the FDA Advisory Committee recommended approval for the treatment of community acquired bacterial pneumonia and complicated skin and skin structure infections. In Oct 2010, the FDA approval was gained for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, including MRSA.
No need register, just fill in contact info below, we will reply you within 24 hours!
Enter the code in the box below: